These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24195728)

  • 1. Emerging drugs for urothelial carcinoma.
    Gartrell BA; Sonpavde G
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
    Joung JY; Kwon WA; Cho IC; Kim EK; Park S; Yoon H; Seo HK; Chung J; Park WS; Lee KH
    Int J Urol; 2011 May; 18(5):350-7. PubMed ID: 21355894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.
    Vaughn DJ
    Cancer Treat Rev; 2008 Jun; 34(4):328-38. PubMed ID: 18262363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
    Sternberg CN; Bellmunt J; Sonpavde G; Siefker-Radtke AO; Stadler WM; Bajorin DF; Dreicer R; George DJ; Milowsky MI; Theodorescu D; Vaughn DJ; Galsky MD; Soloway MS; Quinn DI;
    Eur Urol; 2013 Jan; 63(1):58-66. PubMed ID: 22917984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
    Tsai YS; Tzai TS; Chow NH
    Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemotherapy for urothelial cancer of the bladder--update 2012].
    Niegisch G; Lorch A; Albers P
    Aktuelle Urol; 2012 Dec; 43(6):412-9. PubMed ID: 23196781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel molecular targets for the therapy of urothelial carcinoma.
    Jana BR; Galsky MD; Hahn NM; Milowsky MI; Sonpavde G
    Expert Opin Ther Targets; 2012 May; 16(5):499-513. PubMed ID: 22510032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?
    Balar AV; Milowsky MI
    Cancer; 2015 Jan; 121(2):179-87. PubMed ID: 25091501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
    Ortmann CA; Mazhar D
    Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic chemotherapy for advanced bladder cancer: update and controversies.
    Garcia JA; Dreicer R
    J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A plea for uniform terminology for patients with urothelial carcinoma treated with chemotherapy prior to radical cystectomy: induction versus neoadjuvant chemotherapy.
    Liedberg F; Gudjonsson S; Kollberg P; Ullén A
    Eur Urol; 2015 Oct; 68(4):742-3. PubMed ID: 26047581
    [No Abstract]   [Full Text] [Related]  

  • 13. Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).
    Palacka P; Slopovsky J; Obertova J; Chovanec M; Rejlekova K; Sycova-Mila Z; Kollarik B; Mardiak J; Mego M
    Anticancer Res; 2021 Nov; 41(11):5749-5759. PubMed ID: 34732448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma.
    Huang SY; Wu CC; Hsieh MC; Rau KM; Chiang PH; Sung MT; Luo HL; Huang CC; Huang CH; Liu JM; Su HY
    Oncology; 2020; 98(3):146-153. PubMed ID: 31794969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of current chemotherapy and surgery in advanced and metastatic bladder cancer.
    Racioppi M; D'Agostino D; Totaro A; Pinto F; Sacco E; D'Addessi A; Marangi F; Palermo G; Bassi PF
    Urol Int; 2012; 88(3):249-58. PubMed ID: 22354060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line treatment of metastatic disease: cisplatin-ineligible patients.
    Cathomas R; De Santis M; Galsky MD
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):329-40, x. PubMed ID: 25836938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
    Gallagher DJ; Milowsky MI; Bajorin DF
    Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future directions and targeted therapies in bladder cancer.
    Sonpavde G; Jones BS; Bellmunt J; Choueiri TK; Sternberg CN
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):361-76, x. PubMed ID: 25836940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.
    Fleischmann A; Thalmann GN; Perren A; Seiler R
    Am J Surg Pathol; 2014 Mar; 38(3):325-32. PubMed ID: 24525502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.